Combined Lorlatinib, Dabrafenib, and Trametinib Treatment for ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer with a Lorlatinib-Induced BRAF V600E Mutation: A Case Report

Combined Lorlatinib, Dabrafenib, and Trametinib Treatment for ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer with a Lorlatinib-Induced BRAF V600E Mutation: A Case Report

Dan Li, Jiayin Liu, Xue Zhang, Jing Han, Hui Jin, Long Wang, Li Feng, Zhisong Fan, Jing Zuo, Yudong Wang Department of Medical Oncology, The Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital, Shijiazhuang, People’s Republic of ChinaCorrespondence: Yudong Wang, Departmen...

Full description

Bibliographic Details
Main Authors: Li D, Liu J, Zhang X, Han J, Jin H, Wang L, Feng L, Fan Z, Zuo J, Wang Y
Format: Article
Language:English
Published: Dove Medical Press 2022-11-01
Series:Cancer Management and Research
Subjects:
nsclc
ros1 rearrangement
braf v600e
lorlatinib combined with dabrafenib and trametinib
case report
Online Access:https://www.dovepress.com/combined-lorlatinib-dabrafenib-and-trametinib-treatment-for-ros1-rearr-peer-reviewed-fulltext-article-CMAR

Internet

https://www.dovepress.com/combined-lorlatinib-dabrafenib-and-trametinib-treatment-for-ros1-rearr-peer-reviewed-fulltext-article-CMAR

Similar Items